On19 August 2021 , Oslo Børs resolved to impose violation charge onAker BioMarine ASA , totalingNOK 500,000 for breach of the duty to disclose inside information and for breach of the duty to provide information to Oslo Børs. Oslo Børs has passed the following decision: "For significant breach of the duty to disclose inside information to the market pursuant to Continuing Obligations section 3.1.1 (1), a violation charge is imposed onAker BioMarine ASA ofNOK 350,000 , cf. Continuing Obligations section 12.3 (2) and (3). For significant breach of the duty to provide Oslo Børs with information upon request pursuant to Continuing Obligations section 2.5 (4), a violation charge is imposed onAker BioMarine ASA ofNOK 150,000 , cf. Continuing Obligations section 12.3 (2) and (3)." A brief summary of the case: On24 November 2020 ,Aker BioMarine announced the launch of Lysoveta as a new business segment for the company. Oslo Børs considers that this information constituted inside information no later than in the evening of19 November 2020 and that the duty to disclose the inside information arose at the same time. Furthermore,Aker BioMarine has breached its duty to provide information toOslo Børs by not providing the exchange with information about certain matters in connection with the exchange's inquiries about the matter.
Click here for more information
© Oslo Bors ASA, source